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Abstract 
Desmopressin (dDAVP) is a well‑known peptide analog of the antidiuretic hormone vasopressin, used to prevent 
excessive bleeding during surgical procedures. dDAVP increases hemostatic mediators, such as the von Willebrand 
factor (vWF), recently considered a key element in resistance to metastasis. Studies in mouse models and veterinary 
trials in dogs with locally‑advanced mammary tumors demonstrated that high doses of perioperative dDAVP inhib‑
ited lymph node and early blood‑borne metastasis and significantly prolonged survival. We conducted a phase II 
dose‑escalation trial in patients with breast cancer, administering a lyophilized formulation of dDAVP by intravenous 
infusion in saline, 30–60 min before and 24 h after surgical resection. Primary endpoints were safety and tolerability, as 
well as selection of the best dose for cancer surgery. Secondary endpoints included surgical bleeding, plasma levels of 
vWF, and circulating tumor cells (CTCs) as measured by quantitative PCR of cytokeratin‑19 transcripts. Only 2 of a total 
of 20 patients experienced reversible adverse events, including hyponatremia (grade 4) and hypersensitivity reaction 
(grade 2). Reactions were adequately managed by slowing the infusion rate. A reduced intraoperative bleeding was 
noted with increasing doses of dDAVP. Treatment was associated with higher vWF plasma levels and a postoperative 
drop in CTC counts. At the highest dose level evaluated (2 μg/kg) dDAVP appeared safe when administered in two 
slow infusions of 1 μg/kg, before and after surgery. Clinical trials to establish the effectiveness of adjunctive periopera‑
tive dDAVP therapy are warranted. This trial is registered on www.clinicaltrials.gov (NCT01606072).
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Background
Desmopressin (1-deamino-8-d-arginine vasopressin 
or dDAVP) is a peptide analog of the naturally occur-
ring human antidiuretic hormone, vasopressin. It was 
first synthesized by Zaoral et al. (1967), being a selective 
agonist for the vasopressin V2 cell membrane receptor 
(V2R) present in kidney tubules and endothelia of blood 
vessels. Activation of endothelial V2R by dDAVP causes 
cAMP-mediated signaling followed by the release of von 
Willebrand factor (vWF), coagulation factor VIII and tis-
sue-type plasminogen activator into the blood (Juul et al. 
2014). The hemostatic effects of dDAVP at doses as low 
as 0.2–0.3 µg per kg of body weight make it an often-used 
treatment for the management of bleeding disorders, and 
is also being evaluated as a blood-saving agent in surgery 
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or trauma (Mannucci 1997; Svensson et al. 2014). The evi-
dence for elevated vWF levels as a risk factor for venous 
thromboembolism is weak and dDAVP appears safe for 
perioperative use. The compound has few side effects but 
it is recommended caution in small children and elderly, 
due to the risk of fluid retention and hyponatremia after 
repeated administration (Svensson et al. 2014).
Beyond its role in hemostasis, vWF has emerged as a 
pivotal regulator of tumor cell metastasis. Using a vWF-
deficient mouse model, it was demonstrated that vWF 
plays a protective role against tumor cell dissemination 
in  vivo by inducing apoptosis of metastatic cells, pre-
sumably early after their arrest in the microvasculature 
of the target organ (Terraube et al. 2006, 2007). Interest-
ingly, aggressive human breast cancer cells expressing 
high levels of ADAM28 (a disintegrin and metallopro-
teinase 28) are capable of avoiding vWF-induced apop-
tosis in the circulatory system at micrometastatic sites. 
ADAM28 specifically binds to vWF and renders it inac-
tive by cleaving, thus favoring the survival of metastatic 
cells (Mochizuki et al. 2012). Since physiological levels of 
vWF can induce cancer cell apoptosis, an attractive strat-
egy could be to stimulate endothelial secretion of vWF by 
a pharmacological intervention, such as dDAVP infusion, 
aimed at increasing host resistance to metastasis (Ripoll 
and Alonso 2013).
Vasopressin receptors have been detected in many 
human cancer cell lines (Petit et  al. 2001), including 
breast cancer (North et al. 1995, 1999), and it is known 
that dDAVP exerts some direct antiproliferative effect 
against V2R-expressing human breast carcinoma cells 
(Keegan et  al. 2006). Such action is mediated through 
agonist V2R signaling, involving activation of adenylate 
cyclase with consequent intracellular cAMP elevation 
and protein kinase A activation. The cytostatic effect 
could be blocked by the selective nonpeptide V2R antag-
onists satavaptan (Keegan et al. 2006) and tolvaptan (Ian-
nucci et  al. 2011). In mouse mammary tumor models, 
intravenous (IV) administration of dDAVP prevented the 
development of blood-borne metastases (Alonso et  al. 
1999), and also decreased axillary lymph node involve-
ment when administered at high doses during manipu-
lation and surgical removal of the primary tumor (Giron 
et  al. 2002). In addition, more recent studies in human 
and mouse mammary cancer cells have found that 
dDAVP can induce anti-angiogenic effects associated 
with the proteolytic conversion of plasminogen to angio-
statin (Ripoll et al. 2013).
A pilot veterinary clinical trial in dogs with locally-
advanced mammary cancer showed that a perioperative 
infusion of dDAVP at high doses of 1 μg/kg significantly 
prolonged disease-free and overall survival (Hermo et al. 
2008). It seems that dDAVP infusion during the surgical 
phase not only inhibits perioperative metastatic events 
but also combats micrometastases that occurred before 
surgery. An extended veterinary trial confirmed these 
observations, demonstrating a reduced incidence of local 
relapses and lung metastasis in perioperatively treated 
animals, and a particular survival benefit in cases with 
high-grade carcinoma (Hermo et al. 2011).
Considering the well-known hemostatic effect and tol-
erability of dDAVP as well as its potential antimetastatic 
properties, we conducted a phase II dose-escalation 
trial in patients with breast cancer, administering a lyo-
philized formulation of dDAVP by IV infusion in saline, 
before and after surgical resection of primary tumor.
Patients and methods
Patients
Patients were enrolled from the “Eva Peron” Hospital, San 
Martin and the Italian Hospital, La Plata (Argentina). Eli-
gible patients were otherwise healthy women between 18 
and 65 years of age, with histological and/or cytological 
diagnosis of breast carcinoma (Stage 0, I, II) and managed 
by mastectomy or lumpectomy as primary treatment, 
including sentinel lymph node biopsy. Exclusion criteria 
included pregnancy or breast-feeding, hormonal treat-
ment, known hypersensitivity to dDAVP or vasopressin, 
severe von Willebrand’s disease or hemophilia, syndrome 
of inadequate secretion of antidiuretic hormone, renal 
impairment or hyponatremia, congestive heart failure, 
blood hypertension, heart arrhythmia, thromboembolic 
disease, diabetes type I or II, any underlying coronary 
disease detected in pre-surgical evaluations, symptoms 
or evidence of metastasis on images and other malignant 
diseases. All patients provided written informed consent. 
The study was approved by the ethics committee at each 
site and by the National Administration of Drugs, Food 
and Medical Technology (ANMAT) in Argentina (No. 
NCT01606072).
Study design
This was an open-label, dose-escalation phase II trial. Pri-
mary endpoints were safety and tolerability in breast can-
cer patients undergoing surgery as first treatment, as well 
as selection of the best dose of dDAVP for perioperative 
use in oncology. Secondary endpoints included surgical 
bleeding, plasma levels of vWF, and circulating tumor 
cells (CTCs).
Perioperative administration of study treatment 
and anesthesia
Eligible patients were administered with dDAVP divided 
into 2 IV infusions, the first started preoperatively 
30–60 min before surgery and the second postoperatively 
24 h later. A lyophilized formulation of dDAVP (Surprex 
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TM, Elea Laboratories, Buenos Aires, Argentina) was 
diluted in 100  mL of saline solution and slowly infused 
over the course of approximately 20–30 min. Five groups 
of at least four patients each received increasing total 
dDAVP doses of 0.5, 1.0, 1.25, 1.5 and 2.0 μg/kg, accord-
ing to the scheme in Table  1. If no dose-limiting toxic-
ity occurred, dosages were escalated to the next cohort of 
patients.
Anesthesia was induced and maintained by target-con-
trolled infusion of remifentanil (1–4 μg/kg) and propo-
fol (1.5  mg/kg).  Vecuronium bromide (0.1  mg/kg)  was 
administered for muscle relaxation and endotracheal 
intubation. All patients were pre-oxygenated for 3  min 
with 100 % oxygen using face mask ventilation.
Safety assessments
Safety and tolerability were assessed for all enrolled 
patients  from the time the patient signs  the informed 
consent through post-treatment follow-up. Adverse 
events were graded according to the NCI Common Tox-
icity Criteria for Adverse Events (CTCAE, Version 4.0). 
Serious adverse events were reported to the  sponsor 
and the ethics committees and were followed up until 
resolution.
Biochemical analysis
Blood was drawn within 7 days prior to surgery to obtain 
a baseline, and postoperatively 90–120 min after the first 
and the second dose of dDAVP. All laboratory assays 
were performed  by investigators blinded to the clini-
cal data, as described elsewhere (Sanchez-Luceros et al. 
2010). The vWF antigen (vWF:Ag) was measured by 
ELISA. The functional activity of vWF was analyzed by 
the von Willebrand ristocetin cofactor (vWF:RCo) assay 
using formalin-fixed platelets. The factor VIII levels 
(FVIII:C) were assayed applying the one-stage method. 
The standard pool was periodically calibrated against 
the WHO International Standard for FVIII and vWF in 
plasma (07/316).
Quantitative real‑time reverse transcription‑PCR (qPCR) 
detection of CTCs
CTCs were measured by qPCR assay for expression of 
cytokeratin-19 (CK-19) mRNA in whole blood (Ring et al. 
2005). Total RNA was purified from peripheral blood 
stored in guanidine thiocyanate (Promega, Madison, WI) 
using QuickZol reagent (Kalium Technologies, Buenos 
Aires, Argentina). DNase treatment was carried out using 
a DNase I amplification grade kit (Life Technologies, 
Breda, the Netherlands) according to the manufacturer’s 
instructions. The RNA pellets were dissolved in nucle-
ase-free water and stored at −70  °C prior to use. RNA 
was reverse transcribed with SuperScript III first-Strand 
kit (Life Technologies) according to the manufacturer’s 
protocol. Real-time PCR was performed with SYBR 
Green PCR Master Mix (Life Technologies) and Ste-
pOne Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA, USA). The following specific primers were 
used as described elsewhere (Ring et al. 2005): for CK-19, 
forward: 5′-TGC GGG ACA AGA TTC TTG GT-3′ 
and reverse: 5′-TCT CAA ACT TGG TTC GGA AGT 
CA-3′; for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), forward: 5′-CAT GGG TGT GAA CCA TGA 
GA-3′ and reverse: 5′-CAG TGA TGG CAT GGA CTG 
TG-3′. All sample plates were run with positive controls 
(RNA from MCF-7 human breast cancer cell line) and no 
template negative controls. The following thermal cycling 
conditions were used: 48 °C for 30 min, 95 °C for 10 min, 
40 cycles of 95 °C for 15 s followed by 60 °C for 60 s. Each 
sample was analyzed in triplicate and mean cycle thresh-
old (Ct) values were used for further analysis. Ct values for 
CK-19 were normalized for GAPDH expression levels and 
expressed in relation to positive control samples. Relative 
quantification (RQ) values were calculated as 2−ΔΔCt.
Immunohistochemical detection of V2R
Breast tumor samples were fixed in 10  % formalin, 
embedded in paraffin, and tissue sections of 4  µm were 
cut and placed on silane coated slides. Immunohisto-
chemistry was performed on a Bond automated sys-
tem (Leica Biosystems, Newcastle, UK). Sections were 
dewaxed and pretreated with the epitope retrieval 
solution 2 (EDTA buffer, pH 8.8) at 100  °C for 20  min. 
Immunostaining was carried out using polyclonal rabbit 
antibodies against the human V2R (V5514; 1:100 dilu-
tion, Sigma-Aldrich) at room temperature for 20  min, 
and a  biotin-free, polymeric horseradish peroxidase 
(HRP)-linked antibody conjugate as a secondary anti-
body. Sections were counterstained with hematoxylin. 
Kidney tubules, as well as V2R-expressing MCF-7 human 
breast cancer xenografts generated in nude mice (Garona 
Table 1 Treatment groups, dosage and schedule of admin-
istration of perioperative dDAVP
Group First dose (µg/kg)  
30–60 min 
before surgery





1 0.25 0.25 0.5
2 0.5 0.5 1.0
3 0.75 0.5 1.25
4 1.0 0.5 1.5
5 1.0 1.0 2.0
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et  al. 2015), were used as positive controls for V2R 
expression.
Statistical analysis
PRISM 6, Version 6.01 (GraphPad Software Inc, La Jolla, 
CA, USA) was used to conduct all statistical analyses. 
P values less than 0.05  were considered statistically  sig-
nificant. For multiple group comparisons one-way or 
two-way ANOVA, followed by Tukey post hoc test were 
applied after normal distribution of data was confirmed 
using the Shapiro–Wilk normality test. In addition, the 
homoscedasticity was determined with Bartlett’s test. For 
non-normally distributed data or when homoscedasticity 
was not supported, Kruskal–Wallis test was performed. 
The cut-off value for CK-19 mRNA was determined with 
receiver operating characteristics (ROC) curve analysis 
(minimal false-negative and false-positive results).
Results
The trial accrued a total of 21 patients from April 2012 
to February 2014. One patient who developed a hyper-
tensive episode during the night before surgery was 
ineligible and excluded from the study. Characteris-
tics of the enrolled patients are summarized in Table 2. 
Among the 20 patients evaluable for toxicity, adverse 
events attributable to dDAVP were observed in two 
patients and all were reversible. Laboratory exami-
nations of one patient included in treatment group 3 
(1.25 μg/kg) showed hyponatremia (serum sodium lev-
els <120 mEq/L, grade 4) 1 h after the first dDAVP dose. 
The patient also experienced nausea and mild dyspnea 
(grade 1). These events were considered non-serious as 
they were transient and reversible, and hyponatremia 
was spontaneously corrected 24  h later (137  mEq/L). 
Another patient of treatment group 4 (1.5  μg/kg) 
showed signs of a hypersensitive reaction early after 
starting the preoperative dDAVP infusion, manifest-
ing hot flushing, skin rash and palpitations (grade 2). 
This event was considered serious and treatment was 
interrupted before completion of the first dose. Patient 
was medicated IV with diphenhydramine (20  mg) and 
dexamethasone (8  mg), showing complete resolu-
tion of symptoms within 45  min. Since treatment was 
interrupted, this patient was not evaluable for second-
ary endpoints. Reactions were adequately managed by 
slowing the infusion rate of dDAVP to 30–40  min in 
treatment group 5 (2  μg/kg). The maximum tolerated 
dose was not reached, and the individual dose of 1 μg/
kg given preoperatively and postoperatively was then 
considered for further studies. Median follow-up was 
24 months (range 17–39 months). None of the patients 
relapsed during follow-up.
A reduced intraoperative bleeding of up to 50  % was 
noted with increasing doses of dDAVP, as measured by 
the number or weight of pads used during surgical pro-
cedure (Fig. 1a, b). A significant reduction was observed 
in the number of surgical pads used in patients receiv-
ing a preoperative first dose of dDAVP of 1 μg/kg (treat-
ment groups 4 and 5, considered together) in comparison 
to lower doses (see also Fig.  1a). As expected, vWF:Ag 
plasma levels exhibited a mean increase of 50–100  % 
with respect to baseline after each preoperative and post-
operative dDAVP infusion, and maximum levels were 
obtained in patients of group 5 treated with the high-
est total dose of 2  μg/kg (Fig.  1c). Similar results were 
found for vWF:RCo (Fig. 1d) and FVIII:C levels (data not 
shown).
Evaluable samples were available for CTCs assessment 
from 16 of the 20 patients enrolled. A preliminary analy-
sis indicated no significant differences between treat-
ment groups, and thus data were pooled together due to 
the small number of patients. Detectable levels of CK-19 
mRNA were found in several patients, and 9 of the 16 
patients had high RQ values of >0.05 before surgery at 
baseline (Fig. 2). Twenty-four hours after surgery, only 5 
patients showed high RQ values and also the median lev-
els of expression were reduced. Two weeks later, median 
values remained reduced, but returned to baseline 
1 month after surgery.
Table 2 Descriptive characteristics of  patients enrolled 
in the study (n = 20)
Patient characteristic No.
Age, median (range) 47 years (36–62)
Tumor size, median (range) 20 mm (5–40)
Histopathology
 Ductal carcinoma in situ (DCIS) 4 (20 %)
 Invasive ductal carcinoma 15 (75 %)
 Invasive lobular carcinoma 1 (5 %)
Axillary involvement in invasive carcinoma, n = 16 7 (43 %)
Molecular subtype of invasive carcinoma, n = 16
 Luminal (A and B) 11 (69 %)
 Her2 1 (6 %)
 Triple negative 4 (25 %)
V2R status known, n = 18
 Positive tumor expression 6 (33 %)
Type of surgery
 Breast conserving surgery 12 (60 %)
 Mastectomy 8 (40 %)
Postoperative adjuvant therapy
 None (DCIS) 4 (20 %)
 Cyclophosphamide‑based chemotherapy 6 (30 %)
 Radiotherapy 3 (15 %)
 Chemoradiotherapy 7 (35 %)
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We examined the expression of V2R by immunohis-
tochemistry in paraffin tumor samples available from 18 
patients. In all cases, V2R was detected in endothelial 
cells of small vessels of tumor stroma or surrounding 
tissues. Six of the 18 cases evaluated revealed positive 
expression of V2R in breast carcinoma cells (Fig.  3; see 
also Table 2). Expression pattern was cytoplasmic, either 
diffuse or focal, with membrane accentuation, and the 
intensity of staining ranged from moderate to strong.
Discussion
Pioneer works by Mannucci et al. (1977, 1981) in healthy 
subjects and patients with hemophilia A and von 
Willebrand´s disease demonstrated a good tolerance 
and efficacy of dDAVP as a hemostatic agent at doses 
up to 0.5  μg/kg by the IV route. However, since single 
doses of 0.2–0.3 μg/kg seemed to produce a near-max-
imal response in healthy subjects a reduction in dosage 
was suggested, in order to reduce side effects such as 
tachycardia (Mannucci et  al. 1981). There are anecdotal 
case reports that document the satisfactory periopera-
tive use of dDAVP in oncology patients with hemostatic 
disorders, including a case of a woman with Glanzmann 
thrombasthenia receiving 0.4  μg/kg of the compound 
during the resection of a breast tumor later diagnosed as 
fibroadenoma (Ohishi et al. 1990).
To our knowledge, this is the first dose-escalation trial 
of dDAVP as a perioperative adjunctive treatment in the 
management of operable cancers. The compound was 
well tolerated at the highest total dose level tested in this 
study (2 μg/kg) when administered divided in two slow 
IV infusions of 1 μg/kg, 30–60 min before and 24 h after 
surgery. Two patients developed adverse events, includ-
ing hyponatremia and a hypersensitivity reaction that 
were completely reversible. It is known that the hemo-
static dosage is higher than the dose used for antidiuresis. 
Maximal antidiuretic effect is already achieved with low 
doses, while duration of hemostatic effect tend to prolong 
with increasing doses (Lethagen et  al. 1998). Although 
water retention is not a prominent clinical problem, the 
risk of hyponatremia should be taken into account, par-
ticularly in elderly patients receiving hypotonic solutions 
or after frequently, repeated doses of dDAVP (Svensson 
et al. 2014; Lethagen et al. 1998).
Fig. 1 Hemostatic effects of perioperative dDAVP. a Number and b weight of surgical pads used during the surgical procedure, as a function of 
the preoperative first dose of dDAVP (treatment groups 4 and 5 are presented together, since in both cases received 1 µg/kg). *p < 0.05 (1.0 versus 
0.25 µg/kg), ANOVA with Tukey post‑test. c vWF antigen (vWF:Ag) and d functional vWF (vWF:RCo) levels in samples collected prior to surgery (base-
line), and after the preoperative dose (1st dDAVP dose) and the postoperative dose (2nd dDAVP dose). #p < 0.05 (2.0 µg/kg versus all other dose 
levels), two‑way ANOVA with Tukey post‑test. In all cases, data represent mean ± SEM.
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Intraoperative bleeding can be a major risk for gastro-
intestinal or urologic cancers, but it is not a serious prob-
lem in early-stage breast cancer patients as included in 
this study. However, dDAVP still significantly reduced 
blood loss at a preoperative dose of 1 μg/kg (treatment 
groups 4 and 5) as determined by surgical pads used 
during operation. In this sense, a significantly higher 
increase of vWF was also noted at the highest dose level 
with respect to the other treatment groups. Interestingly, 
vWF is now considered as a versatile multifunctional pro-
tein (Rauch et al. 2013) given its potential role in differ-
ent non-hemostatic processes, like metastasis resistance 
and tumor cell apoptosis (Terraube et al. 2006, 2007). It 
is known that interaction of vWF with metastatic cells is 
mediated via integrin αVβ3, affecting their adhesion and 
survival. However, certain aggressive cancer cells are able 
to escape vWF-induced cell death through production of 
the protease ADAM28 that can counterbalance the pro-
apoptotic function of vWF (Mochizuki et al. 2012).
Preclinical studies in aggressive mouse tumor models 
(Alonso et al. 1999; Giron et al. 2002) and veterinary clin-
ical trials in dogs with locally-advanced mammary cancer 
(Hermo et al. 2008, 2011) have demonstrated inhibition 
of metastatic progression and survival benefit, respec-
tively, of perioperative dDAVP at doses in the range 
of 1–2  μg/kg. In the present clinical trial, CTCs were 
evaluated at different times after perioperative dDAVP 
treatment, as measured by qPCR detection of CK-19 
transcript in peripheral whole blood. An important pro-
portion of blood samples from breast cancer patients 
were positive for CK-19 preoperatively at baseline, but 
median expression levels were reduced early postopera-
tively and also 2  weeks later. One month after surgery, 
CTCs returned to baseline levels. Even though no pla-
cebo or control group underwent surgery was studied, it 
is noteworthy that surgical manipulation of breast can-
cer has been consistently associated with a postopera-
tive increase of CK-19 mRNA-positive cells in peripheral 
blood (Daskalakis et al. 2011; Galan et al. 2002). Thus, it 
seems that administration of dDAVP during the perio-
perative period not only improves hemostatic control 
but also appear to minimize shedding and/or survival of 
breast carcinoma cells.
Recent findings indicated that dDAVP is able to reduce 
tumor angiogenesis by inducing the formation of angio-
statin (Ripoll et al. 2013), a naturally occurring inhibitor 
Fig. 2 Detection of circulating tumor cells (CTCs) by qPCR. CTCc were assessed by means of expression of transcripts for CK‑19 in whole blood, as 
described in detail in “Patients and methods”. Samples from 16 patients were obtained within 7 days prior to surgery (baseline), and 24 h, 2 weeks 
and 1 month after surgery. Data from all treatment groups were pooled. Horizontal lines indicate the median values. The cut‑off RQ value was 
0.00445 for healthy woman volunteers aged 25–61 years, based on ROC analysis (specificity: 100 %; sensibility: 81.25 %; area = 0.91).
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of angiogenesis generated by limited proteolysis of plas-
minogen. V2R-expressing breast cancer cells are stimu-
lated by dDAVP to secrete plasminogen activators such 
as urokinase, thus excising angiostatin from plasmino-
gen. Biological effects of the peptide on both tumor and 
endothelial cells appear complex and required further 
investigations. Notwithstanding, perioperative admin-
istration of dDAVP seems to induce a dual angiostatic 
and antimetastatic effect, breaking cooperative tumor-
endothelium interactions in incipient metastatic lesions 
(Garona and Alonso 2014). Here we explored the expres-
sion of V2R in breast cancer tissues by immunohisto-
chemistry, finding one-third of cases were positive and 
thus may respond with this full dual action. The nega-
tive cases, however, still would benefit from dDAVP 
treatment through endothelial vWF secretion with con-
sequent hemostatic and antimetastatic effects. Further-
more, experimental evidence has suggested a direct role 
of vWF in the modulation of angiogenesis. Inhibition of 
vWF by short interfering RNA in endothelial cells caused 
increased in  vitro angiogenesis and an enhanced vascu-
larization response was observed in vWF-deficient mice 
(Starke et al. 2011).
In conclusion, at the highest dose level evaluated perio-
perative dDAVP appeared to be safe when administered 
in two slow IV infusions of 1 μg/kg, before and after the 
surgical procedure. The results of our study suggest that 
treatment is associated with reduction of intraoperative 
bleeding, higher circulating vWF levels and a drop in 
CTC counts after surgery. Perioperative or early post-
operative therapies should target not only circulating or 
residual cancer cells, but also the wound healing mecha-
nisms usurped by these cells to survive and metastasize 
(Harless 2009). In this regard, the perioperative period is 
an underutilized window of opportunity, where tumor-
host interactions can be modulated to reduce the risk 
of local relapses and metastases (Coffey et al. 2003). We 
believe that the present study provides promising evi-
dence to improve the outcome of breast cancer surgery 
using a well-known hemostatic agent with good tol-
erance. Clinical trials to establish the effectiveness of 
administering adjunctive perioperative dDAVP therapy 
are warranted.
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